Figure 2.

T cell-mediated cytotoxicity of EGFRvIII-DBTE

Real-time target cell viability in tumor-killing assay upon addition of EGFRvIII-DBTE (A) with human T cells, (B) without human T cells, and (C) with human T cells in the absence of EGFRvIII on target cells (U87-MG). (D) Percent cytolysis data in 48-h tumor-killing assay using a series of concentrations of EGFRvIII-DBTE. T cells from four different donors were used to determine EC₅₀ value. E:T ratio was 10:1 for (A)–(D). (E) Percent cytolysis data in 48-h tumor-killing assay using a series of E:T ratios.